- Telehealth visits
Marie Jaeger-Krause, MD
She | Her | HersPediatric Hematology-Oncology (Neuro-Oncology) • Pediatric Hematology-Oncology- Telehealth visits
Marie Jaeger-Krause, MD
She | Her | HersPediatric Hematology-Oncology (Neuro-Oncology) • Pediatric Hematology-Oncology- Telehealth visits
On this page
About me
Dr. Marie Jaeger-Krause is a pediatric hematologist-oncologist who cares for children with cancer and blood disorders. She specializes in treating pediatric brain tumors.
Jaeger-Krause earned her medical degree at Heidelberg University in Germany. After the second year of a residency in pediatrics at University Hospital of Würzburg in Germany, she joined the Salk Institute for Biological Studies in San Diego as a postdoctoral research fellow. In Switzerland, she completed her residency as well as a fellowship in pediatric hematology-oncology at University Children's Hospital Zürich.
Education & training
Fellowship
- Pediatric Hematology-Oncology, Children University Hospital Zurich
Residency
- Pediatrics, Children University Hospital Zurich
- Pediatrics, University Children's Hospital Wurzburg
Degree
- MD, University of Heidelberg School of Medicine
Academic Title
- Health Sciences Clinical Professor
My expertise
Specialties
- Pediatric Hematology-Oncology (Neuro-Oncology)
- Pediatric Hematology-Oncology
Locations
My research
Clinical trials
International Rare Brain Tumor RegistryOpens in a new window
Recruiting
The primary outcome measure will be time from diagnosis to an event, defined as the occurrence of progression or recurrence of the disease, occurrence of a sec...
Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here.
The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.